An interventional study of Belotero® Balance with integral lidocaine and Belotero® Balance in Correction of Moderate to Severe Nasolabial Folds, sponsored by Merz North America, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.
Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Demonstrate the effectiveness of Belotero Balance with lidocaine (Test group) for the reduction of injection-related pain in comparison to Belotero Balance without lidocaine (Control group) for the correction of NLFs.
Identify and describe adverse events (AEs) and serious adverse events (SAEs) during the course of the study. Additionally, common treatment site responses (CTRs) will be assessed.
Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 2 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
Device: Belotero® Balance with integral lidocaine
Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
Device: Belotero® Balance
Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
Also known as: Hyaluronic acid dermal filler with lidocaine, single use syringe
Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
Also known as: Hyaluronic acid dermal filler, single use syringe
Mean Pain Using Visual Analog Scale (VAS)
Pain was assessed using a using a 10 centimeter (cm) VAS. It included 21-numbered circles at 0.5 cm increments, spanning 10 cm total, and was anchored by word descriptors. The VAS scores ranged from 0 (no pain) to 10 (very severe pain).The level of pain was evaluated for each NLF independently immediately upon completion of injection (time zero) on Day 1.
Time frame: Day 1
Percentage of Responders With Greater Than or Equal to (>=) 1-point Improvement as Evaluated Using Merz NLF Scale at Week 6
The Merz NLF scale was used to measure the aesthetic effectiveness of the study products. Each NLF was assessed separately. The Merz NLF scale is a 5-grade scale ranging from 0 (no folds) to 4 (very severe folds). Response was defined \>=1-point improvement on the Merz NLF Scale for each NLF compared to baseline.
Time frame: Week 6
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to Week 6
Number of Participants With Incidence of Any Common Treatment Site Response (CTR) Evaluated Using Participant Diaries
CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.
Time frame: Baseline up to Week 6
Number of Participants With Incidence of Any CTR by Severity Evaluated Using Participant Diaries
CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.
Time frame: Baseline up to Week 6
Number of Participants With Incidence of Any CTR by Duration Evaluated Using Participant Diaries
CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.
Time frame: Baseline up to Week 6
The study was conducted at 3 investigative sites in the United States.
| Milestone | Belotero Balance With or Without Lidocaine |
|---|---|
| Started | 52 |
| Completed | 51 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
Pain was assessed using a using a 10 centimeter (cm) VAS. It included 21-numbered circles at 0.5 cm increments, spanning 10 cm total, and was anchored by word descriptors. The VAS scores ranged from 0 (no pain) to 10 (very severe pain).The level of pain was evaluated for each NLF independently immediately upon completion of injection (time zero) on Day 1.
| score on a scale | Test Product: BBL | Control Product: BB |
|---|---|---|
| Mean Pain Using Visual Analog Scale (VAS) | 3.07 ± 1.88 | 5.94 ± 2.41 |
The Merz NLF scale was used to measure the aesthetic effectiveness of the study products. Each NLF was assessed separately. The Merz NLF scale is a 5-grade scale ranging from 0 (no folds) to 4 (very severe folds). Response was defined \>=1-point improvement on the Merz NLF Scale for each NLF compared to baseline.
| percentage of participants | Test Product: BBL | Control Product: BB |
|---|---|---|
| Percentage of Responders With Greater Than or Equal to (>=) 1-point Improvement as Evaluated Using Merz NLF Scale at Week 6 | 51.0 | 52.9 |
| participants | Belotero Balance With or Without Lidocaine |
|---|---|
| TEAEs | 5 |
| SAEs | 0 |
CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.
| participants | Test Product: BBL | Control Product: BB |
|---|---|---|
| Number of Participants With Incidence of Any Common Treatment Site Response (CTR) Evaluated Using Participant Diaries | 41 | 45 |
CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.
| participants | Test Product: BBL | Control Product: BB |
|---|---|---|
| Mild | 23 | 24 |
| Moderate | 14 | 18 |
| Severe | 4 | 3 |
CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.
| participants | Test Product: BBL | Control Product: BB |
|---|---|---|
| 1 to 3 days | 16 | 20 |
| 4 to 7 days | 14 | 14 |
| 8 to 17 days | 8 | 9 |
| 15 to 30 days | 3 | 2 |
| Greater than (>) 30 days | 0 | 0 |
Collected over Baseline up to Week 6. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belotero Balance With or Without Lidocaine | 0/52 (0%) | 0/52 (0%) | 5/52 (9.6%) |
| Event | Belotero Balance With or Without Lidocaine |
|---|---|
| HeadacheNervous system disorders | 2/52 |
| GastroenteritisInfections and infestations | 1/52 |
| ContusionInjury, poisoning and procedural complications | 1/52 |
| Skin tightnessSkin and subcutaneous tissue disorders | 1/52 |
The safety evaluation set (SES) included all participants who were enrolled into the study, randomized, and received an injection.
| Age, Continuous(years) | Belotero Balance With or Without Lidocaine |
|---|---|
| Mean | 58.4 ± 10.2 |
| Sex: Female, Male(Participants) | Belotero Balance With or Without Lidocaine |
|---|---|
| Female | 47 |
| Male | 5 |
| Race/Ethnicity, Customized(Participants) | Belotero Balance With or Without Lidocaine |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic and not Latino | 51 |
| Race/Ethnicity, Customized(Participants) | Belotero Balance With or Without Lidocaine |
|---|---|
| Black or African American | 16 |
| Caucasian | 36 |
| Region of Enrollment(Participants) | Belotero Balance With or Without Lidocaine |
|---|---|
| United States | 52 |
| Fitzpatrick Skin Type(Participants) | Belotero Balance With or Without Lidocaine |
|---|---|
| Skin Type I | 1 |
| Skin Type II | 20 |
| Skin Type III | 15 |
| Skin Type IV | 4 |
| Skin Type V | 5 |
| Skin Type VI | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Dec 2017, 2 months.
Results were first posted in Oct 2019, 1 year 9 months after primary completion. A results delay was requested in Nov 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.